^
Association details:
Biomarker:No biomarker
Cancer:Osteosarcoma
Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) +
everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
11/20/2020
Excerpt:
Osteosarcoma: Second-line therapy (relapsed/refractory or metastatic disease)…Other Recommended Regimens…Sorafenib + everolimus (category 2B)